Development of supportive management to prevent docetaxel-induced peripheral neuropathy with compression therapy.

JRCT ID: jRCTs072180038

Registered date:13/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: breast cancer
• Date of first enrollment: 09/01/2018
• Target sample size: 87
• Study type: Interventional

Intervention(s)

Control group: Patients who received docetaxel every 3 weeks without compression therapy between 2012 and 2016.
Interventional group: Patients will received docetaxel, with compression in their upper and lower limbs for 24 hours from the beginning of docetaxel.

Outcome(s)

• Primary Outcome: Incidence of all grade peripheral neuropathy
• Secondary Outcome: Incidence of peripheral neuropathy according grade, Incidence of peripheral neuropathy in each course of docetaxel, Completion rates of compression therapy, Safety of compression therapy, Relative dose intensity

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: <= 79age old
• Gender: Female
• Include criteria: Patients who is going to have chemotherapy (docetaxel)
• Exclude criteria: Patients who have peripheral neuropathy

Related Information

• Primary Sponsor: Eguchi Susumu
• Secondary ID(s): UMIN000027881